Levosimendan limits reperfusion injury in a rat middle cerebral artery occlusion (MCAO) model

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Hein, Marc ^a   Zoremba, Norbert ^a   Bleilevens, Chistian ^a   Bruells, Christian ^a   Rossaint, Rolf ^a   Roehl, Anna B ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Cerebral reperfusion injury; Experimental stroke; Levosimendan; Postconditioning

Indexed keywords

ESKETAMINE; INTERCELLULAR ADHESION MOLECULE 1; LEVOSIMENDAN; TUMOR NECROSIS FACTOR ALPHA; XYLAZINE; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; BLOOD PRESSURE; BOLUS INJECTION; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN INFARCTION SIZE; CONTROLLED STUDY; GENERAL ANESTHESIA; IN VITRO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RAT; REPERFUSION INJURY; SWELLING; TRANSIENT ISCHEMIC ATTACK; UPREGULATION; WISTAR RAT; ANIMAL; BRAIN CIRCULATION; BRAIN ISCHEMIA; CEREBRAL ARTERY DISEASE; DRUG EFFECTS; GENETICS; PATHOLOGY; STROKE;

ANIMALS; BLOOD PRESSURE; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; HYDRAZONES; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; PYRIDAZINES; RATS; RATS, WISTAR; REPERFUSION INJURY; STROKE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881141441     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-106     Document Type: Article

References (39)

1. Nogueira RG, Yoo AJ, Buonanno FS, Hirsch JA. Endovascular approaches to acute stroke, part 2: a comprehensive review of studies and trials. AJNR Am J Neuroradiol 2009, 30:859-875. 10.3174/ajnr.A1604, 19386727.
2. Shuaib A, Butcher K, Mohammad AA, Saqqur M, Liebeskind DS. Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. The Lancet Neurology 2011, 10:909-921.
3. Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke 2012, 7:407-418. 10.1111/j.1747-4949.2012.00770.x, 22394615.
4. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 2007, 87:179-197. 10.1016/j.pbb.2007.04.015, 17521716.
5. Das B, Sarkar C. Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model. Vascul Pharmacol 2007, 47:248-256. 10.1016/j.vph.2007.06.008, 17728191.
6. Mayanagi K, Gaspar T, Katakam PV, Busija DW. Systemic administration of diazoxide induces delayed preconditioning against transient focal cerebral ischemia in rats. Brain Res 2007, 1168:106-111.
7. Lafci B, Yasa H, Ilhan G, Ortac R, Yilik L, Kestelli M, Goktogan T, Gurbuz A. Protection of the spinal cord from ischemia: comparative effects of levosimendan and iloprost. Eur Surg Res 2008, 41:1-7. 10.1159/000121394, 18354255.
8. Katircioglu SF, Seren M, Parlar AI, Turan NN, Manavbasi Y, Aydog G, Cicekcioglu F, Tutun U, Ulus AT. Levosimendan effect on spinal cord ischemia-reperfusion injury following aortic clamping. J Card Surg 2008, 23:44-48. 10.1111/j.1540-8191.2007.00486.x, 18290886.
9. Roehl AB, Hein M, Loetscher PD, Rossaint J, Weis J, Rossaint R, Coburn M. Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury. BMC Neurol 2010, 10:97. 10.1186/1471-2377-10-97, 2978146, 20964834.
10. Roehl AB, Zoremba N, Kipp M, Schiefer J, Goetzenich A, Bleilevens C, Kuhn-Velten N, Tolba R, Rossaint R, Hein M. The effects of levosimendan on brain metabolism during initial recovery from global transient ischaemia/hypoxia. BMC Neurol 2012, 12:81. 10.1186/1471-2377-12-81, 3492141, 22920500.
11. Hein M, Roehl AB, Baumert JH, Scherer K, Steendijk P, Rossaint R. Anti-ischemic effects of inotropic agents in experimental right ventricular infarction. Acta Anaesthesiol Scand 2009, 53:941-948. 10.1111/j.1399-6576.2009.01994.x, 19426242.
12. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council Guide for the care and use of laboratory animals 1996, Washington, D.C: National Academy Press, 7, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council.
13. Bleilevens C, Roehl AB, Goetzenich A, Zoremba N, Kipp M, Dang J, Tolba R, Rossaint R, Hein M. Effect of anesthesia and cerebral blood flow on neuronal injury in a rat middle cerebral artery occlusion (MCAO) model. Exp Brain Res 2013, 224:155-164. 10.1007/s00221-012-3296-0, 23064810.
14. Garcia JH, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 1995, 26:627-634. 10.1161/01.STR.26.4.627, 7709410.
15. Ryang Y, Dang J, Kipp M, Petersen K, Fahlenkamp AV, Gempt J, Wesp D, Rossaint R, Beyer C, Coburn M. Solulin reduces infarct volume and regulates gene-expression in transient middle cerebral artery occlusion in rats. BMC Neurosci 2011, 12:113. 10.1186/1471-2202-12-113, 3251036, 22082476.
16. Kramer M, Dang J, Baertling F, Denecke B, Clarner T, Kirsch C, Beyer C, Kipp M. TTC staining of damaged brain areas after MCA occlusion in the rat does not constrict quantitative gene and protein analyses. J Neurosci Methods 2010, 187:84-89. 10.1016/j.jneumeth.2009.12.020, 20064557.
17. Robin E, Simerabet M, Hassoun SM, Adamczyk S, Tavernier B, Vallet B, Bordet R, Lebuffe G. Postconditioning in focal cerebral ischemia: role of the mitochondrial ATP-dependent potassium channel. Brain Res 2011, 1375:137-146.
18. Munakata H, Okada K, Hasegawa T, Hino Y, Kano H, Matsumori M, Okita Y. Controlled low-flow reperfusion after warm brain ischemia reduces reperfusion injury in canine model. Perfusion 2010, 25:159-168. 10.1177/0267659110370068, 20421252.
19. Choi SK, Lee G, Choi S, Kim YJ, Park H, Park BJ. Neuroprotective effects by nimodipine treatment in the experimental global ischemic Rat model. Real time estimation of glutamate. J Korean Neurosurg Soc 2011, 49:1. 10.3340/jkns.2011.49.1.1, 3070888, 21494355.
20. Kang SW, Choi S, Park E, Chae S, Choi S, Jin Joo H, Lee G, Park H. Neuroprotective effects of magnesium-sulfate on ischemic injury mediated by modulating the release of glutamate and reduced of hyperreperfusion. Brain Res 2011, 1371:121-128.
21. Armstead WM, Kiessling JW, Riley J, Kofke WA, Vavilala MS. Phenylephrine infusion prevents impairment of ATP- and calcium-sensitive potassium channel-mediated cerebrovasodilation after brain injury in female, but aggravates impairment in male, piglets through modulation of ERK MAPK upregulation. J Neurotrauma 2011, 28:105-111. 10.1089/neu.2010.1581, 3019588, 20964536.
22. Domoki F, Perciaccante JV, Veltkamp R, Bari F, Busija DW. Mitochondrial potassium channel opener diazoxide preserves neuronal-vascular function after cerebral ischemia in newborn pigs. Stroke 1999, 30:2713-2718. discussion 2718-9, 10.1161/01.STR.30.12.2713, 10583002.
23. Bravo MC, López P, Cabañas F, Pérez-Rodríguez J, Pérez-Fernández E, Pellicer A. Acute effects of levosimendan on cerebral and systemic perfusion and oxygenation in newborns: an observational study. Neonatology 2011, 99:217-223. 10.1159/000314955, 20881438.
24. Liva Cengiz T, Fatih Erdi M, Tosun M, Atalik E, Cihat Avunduk M, Cavide Sönmez F, Mehmetoglu T, Baysefer A. Beneficial effects of levosimendan on cerebral vasospasm induced by subarachnoid haemorrhage: an experimental study. Brain Inj 2010, 24:877-885. 10.3109/02699051003789260, 20433288.
25. Dittmar M. External carotid artery territory ischemia impairs outcome in the endovascular filament model of middle cerebral artery occlusion in rats. Stroke 2003, 34:2252-2257. 10.1161/01.STR.0000083625.54851.9A, 12893948.
26. Segreti JA, Marsh KC, Polakowski JS, Fryer RM. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure. Journal of Pharmacology and Experimental Therapeutics 2008, 325:331-340. 10.1124/jpet.107.132530, 18171907.
27. Zhu H, Luo W, Wang H. Iptakalim protects against hypoxic brain injury through multiple pathways associated with ATP-sensitive potassium channels. Neuroscience 2008, 157:884-894. 10.1016/j.neuroscience.2008.09.033, 18951957.
28. Denes A, Ferenczi S, Kovacs KJ. Systemic inflammatory challenges compromise survival after experimental stroke via augmenting brain inflammation, blood- brain barrier damage and brain oedema independently of infarct size. J Neuroinflammation 2011, 8:164. 10.1186/1742-2094-8-164, 3235982, 22114895.
29. Vemuganti R, Dempsey RJ, Bowen KK. Inhibition of intercellular adhesion molecule-1 protein expression by antisense oligonucleotides is neuroprotective after transient middle cerebral artery occlusion in rat. Stroke 2004, 35:179-184.
30. Xu X, Zhang S, Yan W, Li X, Zhang H, Zheng X. Development of cerebral infarction, apoptotic cell death and expression of X-chromosome-linked inhibitor of apoptosis protein following focal cerebral ischemia in rats. Life Sci 2006, 78:704-712. 10.1016/j.lfs.2005.05.080, 16139848.
31. Timaru-Kast R, Wyschkon S, Luh C, Schaible E, Lehmann F, Merk P, Werner C, Engelhard K, Thal SC. Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma. Crit Care Med 2012, 40:935-944. 10.1097/CCM.0b013e31822f08b9, 21926585.
32. Sheng SP, Lei B, James ML, Lascola CD, Venkatraman TN, Jung JY, Maze M, Franks NP, Pearlstein RD, Sheng H, Warner DS. Xenon neuroprotection in experimental stroke. Anesthesiology 2012, 117:1262-1275. 10.1097/ALN.0b013e3182746b81, 23143806.
33. Ulbrich C, Zendedel A, Habib P, Kipp M, Beyer C, Dang J. Long-term cerebral cortex protection and behavioral stabilization by gonadal steroid hormones after transient focal hypoxia. J Steroid Biochem Mol Biol 2012, 131:10-16. 10.1016/j.jsbmb.2012.01.007, 22326729.
34. Haelewyn B, Rouillon C, Risso J, Abraini JH. Functional (neurologic) recovery following transient focal cerebral ischemia in the rat requires at least 80% of ipsilateral cortical and subcortical integrity. Exp Neurol 2008, 213:238-240. 10.1016/j.expneurol.2008.05.012, 18599041.
35. David HN, Leveille F, Chazalviel L, MacKenzie ET, Buisson A, Lemaire M, Abraini JH. Reduction of ischemic brain damage by nitrous oxide and xenon. J Cereb Blood Flow Metab 2003, 23:1168-1173.
36. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009, 40:2244-2250. 10.1161/STROKEAHA.108.541128, 2888275, 19246690.
37. Encarnacion A, Horie N, Keren-Gill H, Bliss TM, Steinberg GK, Shamloo M. Long-term behavioral assessment of function in an experimental model for ischemic stroke. J Neurosci Methods 2011, 196:247-257. 10.1016/j.jneumeth.2011.01.010, 3539723, 21256866.
38. Ström JO, Ingberg E, Theodorsson A, Theodorsson E. Method parameters' impact on mortality and variability in rat stroke experiments: a meta-analysis. BMC Neurosci 2013, 14:41. 10.1186/1471-2202-14-41, 3637133, 23548160.
39. Yoshimura S, Toyoda K, Ohara T, Nagasawa H, Ohtani N, Kuwashiro T, Naritomi H, Minematsu K. Takotsubo cardiomyopathy in acute ischemic stroke. Ann Neurol 2008, 64:547-554. 10.1002/ana.21459, 18688801.